Affimed (NASDAQ:AFMD) is set to release its earnings data before the market opens on Wednesday, May 22nd. Analysts expect Affimed to post earnings of ($0.16) per share for the quarter.
Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Wednesday, March 27th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.34. The company had revenue of $25.96 million during the quarter. Affimed had a negative return on equity of 44.56% and a negative net margin of 87.00%. On average, analysts expect Affimed to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ:AFMD opened at $3.49 on Friday. The firm has a market cap of $214.00 million, a P/E ratio of -9.18 and a beta of 3.23. Affimed has a 52-week low of $1.40 and a 52-week high of $7.35. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.01 and a quick ratio of 3.00.
An institutional investor recently raised its position in Affimed stock. Geode Capital Management LLC grew its stake in Affimed NV (NASDAQ:AFMD) by 29.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,074 shares of the biopharmaceutical company’s stock after purchasing an additional 14,854 shares during the quarter. Geode Capital Management LLC owned approximately 0.11% of Affimed worth $205,000 at the end of the most recent reporting period. 41.10% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently issued reports on the company. Leerink Swann assumed coverage on Affimed in a research note on Thursday, March 28th. They set an “outperform” rating and a $4.17 price objective for the company. ValuEngine lowered Affimed from a “buy” rating to a “hold” rating in a research note on Friday, March 29th. Zacks Investment Research raised Affimed from a “hold” rating to a “strong-buy” rating and set a $4.75 price objective for the company in a research note on Friday, March 29th. Finally, Svb Leerink assumed coverage on Affimed in a research note on Thursday, March 28th. They set an “outperform” rating and a $8.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Affimed presently has an average rating of “Buy” and an average target price of $4.99.
ILLEGAL ACTIVITY NOTICE: “Affimed (AFMD) Set to Announce Earnings on Wednesday” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2019/05/17/affimed-afmd-set-to-announce-earnings-on-wednesday.html.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Story: NASDAQ
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.